IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
出版年份 2015 全文链接
标题
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 7, Pages 1190-1198
出版商
Springer Nature
发表日期
2015-02-20
DOI
10.1038/bjc.2015.64
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis
- (2015) Emilio Bria et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) B. Escudier et al. ANNALS OF ONCOLOGY
- Molecular Biomarkers in Advanced Renal Cell Carcinoma
- (2014) P. Maroto et al. CLINICAL CANCER RESEARCH
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
- (2013) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
- (2013) Charles S. Harmon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
- (2013) Tomohiro Funakoshi et al. CANCER TREATMENT REVIEWS
- Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
- (2013) M. B. Shea et al. CLINICAL CANCER RESEARCH
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
- (2013) Juana Dornbusch et al. PLoS One
- Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future
- (2013) Tobias Janowitz et al. SEMINARS IN ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Current and future systemic treatments for renal cell carcinoma
- (2012) Rosalie Fisher et al. SEMINARS IN CANCER BIOLOGY
- 1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL)
- (2011) Y. Liu et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow
- (2011) A. M. Molina et al. ONCOLOGIST
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started